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Abstract
Background:  Abdominal aortic aneurysms are a common disorder with an incompletely
understood etiology. We used Illumina and Affymetrix microarray platforms to generate global
gene expression profiles for both aneurysmal (AAA) and non-aneurysmal abdominal aorta, and
identified genes that were significantly differentially expressed between cases and controls.
Results: Affymetrix and Illumina arrays included 18,057 genes in common; 11,542 (64%) of these
genes were considered to be expressed in either aneurysmal or normal abdominal aorta. There
were 3,274 differentially expressed genes with a false discovery rate (FDR) ≤ 0.05. Many of these
genes were not previously known to be involved in AAA, including SOST and RUNX3, which were
confirmed using Q-RT-PCR (Pearson correlation coefficient for microarray and Q-RT-PCR data =
0.89; p-values for differences in expression between AAA and controls for SOST: 4.87 × 10-4 and
for RUNX3: 4.33 × 10-5). Analysis of biological pathways, including Gene Ontology (GO) and Kyoto
Encyclopedia of Genes and Genomes (KEGG), indicated extreme overrepresentation of immune
related categories. The enriched categories included the GO category Immune Response
(GO:0006955; FDR = 2.1 × 10-14), and the KEGG pathways natural killer cell mediated cytotoxicity
(hsa04650; FDR = 5.9 × 10-6) and leukocyte transendothelial migration (hsa04670; FDR = 1.1 × 10-5).
Conclusion: Previous studies have provided evidence for the involvement of the immune system
in AAA. The current expression analysis extends these findings by demonstrating broad coordinate
gene expression in immunological pathways. A large number of genes involved in immune function
were differentially expressed in AAA, and the pathway analysis gave these results a biological
context. The data provide valuable insight for future studies to dissect the pathogenesis of human
AAA. These pathways might also be used as targets for the development of therapeutic agents for
AAA.
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Background
Abdominal aortic aneurysm (AAA) is a common, late age-
at-onset disorder affecting approximately 1–6 % of the
population of industrialized countries, and approxi-
mately 9.5% of those 65 years and older [1,2]. Rupture of
AAA has high mortality, and is the 13th leading cause of
death in the United States [1].
The etiology of AAA is complex, with many environmen-
tal and genetic factors contributing to the risk [1,3,4].
AAAs are characterized by signs of local chronic inflam-
mation of the aortic wall, decreased numbers of smooth
muscle cells in the aortic media layer and fragmentation
of the extracellular matrix at the site of the aneurysm [4].
Risk factors have been identified, but the molecular events
responsible for the initiation and progression of AAAs
remain unknown. Many studies have focused on limited
sets of plausible candidate genes, such as those encoding
matrix metalloproteinases (MMPs) and their inhibitors,
but recently microarrays have been used to elucidate a
more global gene expression profile for AAA [4-8].
Previous studies have provided evidence for the involve-
ment of the immune system in AAA formation and pro-
gression [see [9-12]]. Animal models of AAA have been
used to test the contributions of components of the
immune system [13,14]. Cellular involvement of neu-
trophils, T cells, and macrophages has been found to be
important in the formation of AAA in animal models [15-
17]. In addition, various immune-related molecules have
been examined using the AAA models, and molecules
such as NFκB, c-Jun N-terminal kinase, P47phox, IFNγ,
and IL4, among others, have also been shown to be
involved in the formation of an experimental aneurysm
[18-21]. In humans, the cellular immune infiltrates in the
AAA tissue have been characterized by several groups. The
findings indicate that many types of immune cells are
found in AAAs, such as macrophages, neutrophils, natural
killer (NK) cells, T cells, and B cells [22-25]. Changes in
the circulating immune components of AAA patients
included an increase in NK cells and CD4+CD28- T cells,
as well as a decrease in the number of CD4+CD31+ T cells
[26-28]. These findings implicate the immune system in
pathogenesis of AAA, and it has even been asserted that
AAA is autoimmune [29-31]. The precise role of the
immune system in AAA pathophysiology has yet to be elu-
cidated.
The present study utilized two microarray platforms to
generate global mRNA expression profiles for both aneu-
rysmal and non-aneurysmal abdominal aorta. These
results provide valuable information to identify func-
tional pathways involved in the pathogenesis of AAA
without biasing the data by an a priori selection of genes.
The global approach allows identification of the most rel-
evant pathways, and the cross-platform validation pro-
tects against platform-specific artifacts. The current study
does indeed validate some genes that were previously
studied; however, it also extends the findings from the
previous studies, suggests involvement of genes not previ-
ously studied, and in its global aggregate suggests which
components within the pathways are the active compo-
nents.
Results
Aortic wall tissue samples were collected from patients
who underwent repair operations for AAA, and from age,
sex, and ethnicity-matched controls at autopsies (Table
1). RNA isolated from the tissue samples was used in glo-
bal gene expression studies with two different platforms
(Affymetrix and Illumina).
The Affymetrix whole-genome expression chip was run
with 4 RNA pools, while the Illumina platform was run on
13 individual RNA samples and 2 pooled RNA samples
(Table 1). The two independent platforms are compara-
ble, with a total of 18,057 distinct genes (referred to as
RefList) represented on both platforms (Affymetrix:
19,835; Illumina: 20,054). This subset of genes common
to the two platforms was used as the basis for the analyses
so that concordance between the two platforms could be
determined. The genes that were excluded from the RefList
were sparsely annotated (36% GO annotation; 3% KEGG
annotation), consequently the loss of information due to
excluding these genes was negligible.
A total of 11,542 distinct genes (64% of the RefList)
passed the expression criteria of a Detection Score ≥ 0.99 in
either AAA or control groups based on Illumina arrays
(AAA: 11,077; control: 10,478; both: 10,285). The
Affymetrix data indicated that 11,901 (66% of the RefList)
of the genes were expressed, with 9,955 genes considered
expressed by both platforms (55% of the RefList). Con-
sistent with previous findings, increasing detection strin-
gency increased the proportion of genes in common
between the platforms [32]. To be conservative in avoid-
ing false negatives (i.e., to avoid eliminating genes unnec-
essarily) we used a Detection Score ≥ 0.99 from the
Illumina data as our criteria for a gene to be considered
expressed.
Comparison of the profiles between AAA and control
revealed 4,627 genes on the Illumina platform with a
Detection Score ≥ 0.99 and a |DiffScore| ≥ 13 (which
equates to a nominal p-value of ≤ 0.05). Correction for
multiple testing yielded 3,274 distinct differentially
expressed genes (DiffList) with an FDR ≤ 0.05 [see addi-
tional file 1:Table I] [33]. The extreme differences
observed between AAA and control abdominal aorta are
shown in Figure 1 and additional data [see additional fileBMC Genomics 2007, 8:237 http://www.biomedcentral.com/1471-2164/8/237
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2:Table II] for illustrative purposes, and to demonstrate
the concordance of the results between Illumina and
Affymetrix. (The top 100 genes were chosen to provide a
readable list in the figure.) Increasing stringency in the
selection of the differentially expressed genes resulted in
greater concordance between the two platforms [90%
(1,076/1,191) at FDR ≤ 0.001; 96% (465/485) at FDR ≤
1.0 × 10-5]. There were more genes with decreased expres-
sion in AAA (1,793/3,274; 55%) than genes with
increased expression (1,481/3,274; 45%). Therefore, we
selected genes in proportion to increased (45%) and
decreased (55%) expression in AAA for visualization (Fig-
ure 1).
Isoform analysis on this dataset is limited due to the diver-
gent nature of the arrays, i.e., the Affymetrix microarray
used has probesets consisting of multiple oligos from a
transcript making it difficult to calculate individual iso-
form contributions to the overall signal, while the Illu-
mina platform has exact replicates with isoform
information. Using the Illumina platform, 138 of the
3,274 (4%) genes on the DiffList had the largest differen-
tial signal from a particular isoform (as opposed to a gen-
eral probe). An example of one such difference is in CD86
(CD86 antigen; Entrez Gene ID: 942), where the full
length isoform is detected and increased significantly in
AAA, while the shorter transcript variant is not detected in
either condition, which indicates that CD86 is being tran-
scribed by activated as opposed to nonactive monocytes
[34].
We carried out real-time quantitative reverse-transcriptase
PCR (Q-RT-PCR) validation for two genes, SOST (sclero-
steosis) and RUNX3 (runt-related transcription factor 3)
which each were significantly altered according to the
microarray data (Figure 2). The Pearson correlation of the
expression values between the Illumina microarray and
Q-RT-PCR data was 0.89 for the exact replicates (AAA n =
6; control n = 7). Consistent with prior observations, there
was a bias to underestimate the fold-change of highly dif-
ferential genes in the microarray data (Illumina vs. Q-RT-
PCR; SOST: 28 vs. 38; RUNX3: 10 vs. 13) [35].
Inspection of the genes in Figure 1 revealed numerous
genes involved in immune function with 24% having
some connection to immunity (2/55 decreased; 22/45
increased). We subsequently analyzed the 3,274 genes in
the DiffList for enrichment in the Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways and Gene Ontol-
ogy (GO) categories [36-38]. The analysis of KEGG path-
ways revealed 21 enriched non-metabolic pathways
(Table 2). Enriched GO categories corresponded well with
enriched KEGG pathways, with immune-related functions
highly represented in both [e.g., the GO category
"immune response" (GO:0006955) having an FDR= 2.08
x 10-14; not shown]. Since KEGG pathways provide more
Table 1: Sample demographics
Sample ID Type* Sex Age Cause of Death RIN† Type of Experiment‡
A1-F AAA F 82 NA 7.2 MA, QRT
A2-F AAA F 68 NA 7.0 MA, QRT
A3-F AAA F 64 NA 7.9 MA, QRT
A1-M AAA M 64 NA 7.1 MA, QRT
A2-M AAA M 63 NA 6.5 MA, QRT
A3-M AAA M 67 NA 6.9 MA, QRT
A4-M AAA M 63 NA 5.9 MA, QRT
C1-F Control F 74 Lung cancer 6.6 MA, QRT
C2-F Control F 52 Metastatic breast carcinoma 7.7 MA, QRT
C3-F Control F 84 Aortic arch dissection 6.2 MA, QRT
C1-M Control M 65 Peritonitis 8.0 MA, QRT
C2-M Control M 59 Hepatocellular carcinoma 7.4 MA, QRT
C3-M Control M 52 Alcoholic liver cirrhosis 8.5 MA, QRT
C4-M Control M 73 Lung cancer 6.1 MA, QRT
A4-F AAA F 64 NA 5.5 QRT
A5-M AAA M 70 NA 7.8 QRT
A6-M AAA M 63 NA 6.3 QRT
C5-M Control M 41 Congestive heart failure 6.6 QRT
C6-M Control M 45 Ischemic heart disease 6.7 QRT
C7-M Control M 75 Cholangiocarcinoma 4.5 QRT
* AAA samples were obtained during aneurysmal repair operations from live patients. Control samples were obtained from autopsies. All donors 
were Caucasian.
† Agilent BioAnalyzer 2100 RNA integrity number.
‡ MA, microarray; QRT, quantitative real-time RT-PCR. A3-F was analyzed on Affymetrix platform only.BMC Genomics 2007, 8:237 http://www.biomedcentral.com/1471-2164/8/237
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biological information in that they show molecular inter-
actions, further analyses focused on KEGG pathways.
The enriched KEGG pathways are not independent of one
another; many KEGG pathways refer to other KEGG path-
ways, i.e., the pathways interact. This interaction is illus-
trated in Figure 3. The relative size of each pathway in
terms of the number of genes represented is indicated by
the area of the circle, and the proportion of differentially
expressed genes is indicated by the darker shaded seg-
ments. The pathway names in Figure 3 have been short-
ened and the abbreviations can be found in Table 2.
The top five most enriched KEGG pathways are regulation
of actin cytoskeleton (RAC; hsa04810; FDR= 4.71e-09), cell
adhesion molecules (CAM; hsa04514; FDR= 1.63e-07), focal
adhesion (FA; hsa04510; FDR= 1.98e-07), natural killer cell
mediated cytotoxicity (NK; hsa04650; FDR= 5.94e-06), and
leukocyte transendothelial migration (LTEM; hsa04670;
FDR= 1.06e-05), see Table 2.
Q-RT-PCR results for RUNX3 and SOST in AAAs (n = 10)  and control abdominal aortas (n = 10) Figure 2
Q-RT-PCR results for RUNX3 and SOST in AAAs (n = 10) 
and control abdominal aortas (n = 10). Larger values of Max 
– ∆CT represent larger amounts of RNA present, and a 
change of this value by 1 represents a two-fold increase in 
the amount of mRNA. Medians are indicated by horizontal 
lines. See Table 1 for details on samples analyzed.
Heatmap of the 100 most differentially expressed genes in  AAA Figure 1
Heatmap of the 100 most differentially expressed genes in 
AAA. To show consistency of the results between the two 
platforms, both Illumina (15 left columns) and Affymetrix (4 
right columns) results are presented. Sample IDs are on top 
(see Table 1 for details) and gene symbols on the right. A list-
ing of these 100 genes with expression values in both condi-
tions as well as the FDR values is provided [see the additional 
file 2: Table II].BMC Genomics 2007, 8:237 http://www.biomedcentral.com/1471-2164/8/237
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The KEGG pathways RAC, CAM, and FA each participate
in many aspects of biology and, therefore, each interact
with several other KEGG pathways (see Figure 3). In the
RAC pathway, 147/204 probed genes were expressed in
either AAA or controls (AAA: 132; control: 134), and 76 of
the expressed genes (51%) were differentially expressed
between cases and controls. In the CAM pathway, 93/127
probed genes were expressed in either AAA or controls
(AAA: 89; control: 73), and 51 of the expressed genes
(55%) were differentially expressed between cases and
controls. In the FA pathway, 158/208 probed genes were
expressed in either AAA or controls (AAA: 151; control:
148), and 72 of the expressed genes (46%) were differen-
tially expressed between cases and controls. There is con-
siderable overlap between these three pathways and the
NK and LTEM pathways in that 39 of the 127 (31%) genes
in the CAM pathway are also in the NK and LTEM path-
ways. The RAC pathway shares 52 of its 204 (25%) genes
with the NK and LTEM pathways, and the FA pathway
shares 61 of its 208 (29%) genes with these two pathways.
NK and LTEM pathways (Table 2) are more detailed in
their annotations in the KEGG database, and of the top
five enriched pathways also have the most direct biologi-
cal relevance to AAA. In the NK pathway (Figure 4), 86/
127 probed genes were expressed in either AAA or con-
trols (AAA: 84; control: 75). Altogether, 47/86 (55%) of
the expressed genes were differentially expressed between
cases and controls. In the LTEM pathway [see additional
file 3: Figure I], 89/115 probed genes were expressed in
either condition (AAA: 84; control: 79), and 43/89 (48%)
were differentially expressed. Taken together, 75 distinct
genes from these two pathways were differentially
expressed between AAA and control, since 10 genes had
membership in both KEGG pathways. It is also notewor-
thy that 7/75 (9.3%; CYBA,  ITGAL,  LCP2,  PIK3CD,
PTPN6, SYK, VAV1) were among the 100 most differen-
tially expressed genes shown in Figure 1 and additional
data [see additional file 2: Table II]. The expression values
for all the probed genes, and FDR values for those signifi-
cantly different in these pathways, are provided as addi-
tional data [see additional file 4: Table III and additional
file 5: Table IV].
To illustrate the gene-based data, KEGG pathways were
redrawn with genes instead of proteins as seen in Figure 4
and additional data [see additional file 3: Figure I]. This
increased the complexity of the pathways, since multiple
genes occasionally coded for a particular protein type (e.g.
the NFAT proteins), or protein complex. In some
instances where the original KEGG protein symbol
referred to two or more genes, the genes had differential
expression in opposite directions, i.e., some genes had
reduced, and other genes increased expression. An exam-
ple of this is Rac in the NK pathway where RAC1 is
decreased in AAA (FDR= 5.28 × 10-4) and RAC2 is
increased (FDR= 1.16 × 10-5). In the original KEGG path-
way both of the RAC genes that link to the protein in the
KEGG database are represented by the symbol "Rac", and
therefore some of the information of the gene enrichment
Table 2: KEGG biological pathways for differentially expressed genes
KEGG pathway Probed* Observed Expected FDR
Regulation of actin cytoskeleton (RAC) 204 76 36.99 4.71e-09
Cell adhesion molecules (CAMs) 127 51 23.03 1.63e-07
Focal adhesion (FA) 208 72 37.71 1.98e-07
Natural killer cell mediated cytotoxicity (NK) 127 47 23.03 5.94e-06
Leukocyte transendothelial migration (LTEM) 115 43 20.85 1.06e-05
Type I diabetes mellitus (T1DM) 42 20 7.62 1.29e-04
ECM-receptor interaction (ECM) 86 31 15.59 5.69e-04
T cell receptor signaling pathway (T cell) 99 34 17.95 6.93e-04
Hematopoietic cell lineage (HCL) 84 30 15.23 7.03e-04
B cell receptor signaling pathway (B cell) 70 26 12.69 8.65e-04
Adherens junction (AJ) 76 27 13.78 1.38e-03
Gap junction (GJ) 96 32 17.41 1.38e-03
Calcium signaling pathway (Ca2+) 175 50 31.73 2.12e-03
Antigen processing and presentation (AP&P) 79 27 14.32 2.12e-03
Cytokine-cytokine receptor interaction (CCRI) 247 66 44.78 2.12e-03
Tight junction (TJ) 116 36 21.03 2.12e-03
Alzheimer's disease (AD) 22 11 3.99 2.60e-03
MAPK signaling pathway (MAPK) 270 69 48.95 5.10e-03
Long-term potentiation (LTP) 68 21 12.33 2.58e-02
Wnt signaling pathway (WNT) 144 38 26.11 2.87e-02
Axon guidance (AG) 129 34 23.39 4.02e-02
* Probed indicates the number of genes with a membership in a particular pathway and for which probes were available on both microarray 
platforms.BMC Genomics 2007, 8:237 http://www.biomedcentral.com/1471-2164/8/237
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was unavailable even with biological annotation, prior to
our modifications of the KEGG pathways.
Discussion
Multiple etiological factors contribute to AAA, and its
pathobiology is incompletely understood. Experiments
with animal models such as the angiotensin II infusion,
elastase perfusion, and calcium chloride exposure models
[13], in combination with more detailed analysis of the
condition in humans, are beginning to elucidate the
pathobiology. The current study provides a comprehen-
sive, global view of the gene expression in AAA and con-
trol aorta, and the pathway analyses presented extend
previous findings and provide novel insights into the
pathogenesis of AAA.
Genes such as MMP1,MMP9,IL1B,PLAU, PLAUR, and sev-
eral cathepsin family members previously implicated in
the pathogenesis of AAA were among the 3,274 differen-
tially expressed genes. We selected 2 genes, RUNX3 and
SOST, novel to AAA for further study since their expres-
sion was substantially different in opposing directions
between AAA and control. SOST belongs to the DAN fam-
ily of antagonists of the transforming growth factor-beta
(TGF-β) superfamily and also antagonizes Wnt signaling
[39,40]. Its association with TGF-β is interesting since
TGF-β is involved in the Marfan syndrome which has aor-
tic dissection as a characteristic feature [41]. Wnt signaling
is involved in many aspects of the vasculature including
arterial response to angiotensin II, used to induce AAA in
animal models [13]. Together, these lines of evidence sug-
gest that SOST is important in AAA pathogenesis. RUNX3
also has a role in TGF-β signaling and apoptosis [42], and
it is involved in the differentiation of T cells from CD4+ to
CD8+ lineages [43].
The enrichment seen in biological pathways provides
greater understanding of the processes that may be
involved in AAA. This comprehensive approach of gene
expression analysis, utilizing annotated pathways rather
than isolated genes, as well as the interconnectedness of
the pathways (Figure 3), gives a more global picture of the
pathology involved in AAA. In addition, subtle changes
can be understood, rather than overlooked, when exam-
ined in the context of biological processes. Not all path-
ways are equally informative; it should be noted that the
enrichment of some pathways, e.g., RAC, CAM and FA,
while highly interesting, lack the specificity of the smaller
KEGG pathways, and consequently relevance to AAA is
not as obvious. Since the number of overlapping genes in
these three pathways and the NK and LTEM pathways was
considerable, it is reasonable to conclude that the contri-
bution of the immunological processes in AAA may also
contribute to the observed enrichment of these pathways.
The NK pathway (Figure 4) is interesting because immune
involvement has been implicated in AAA [25,28,44-47].
The biological processes involved in mediating NK cyto-
toxicity are not restricted to NK cells alone, but are com-
mon to several types of cytotoxic immune cells, including
cytotoxic T lymphocytes, NK T cells, and γδ T cells [48].
Although NK cells have been found in AAA tissue, they
represent a small fraction of the immune cells present
[25]. The gene expression levels in this pathway are likely
to be the result of more than one cytotoxic cell type, and
further work is necessary to determine the exact composi-
tion of the cellular infiltrate and their individual contribu-
tions to the increased levels of the genes in this pathway.
Several genes shown in the NK (Figure 4) and LTEM path-
ways [see additional file 3: Figure I] with dashed orange
and purple outlines were identified as expressed exclu-
sively in either AAA or control aorta, but had an FDR >
0.05, i.e., the genes did not pass the FDR ≤ 0.05 threshold
for differential expression, but were interesting because
their expression was not detectable in one of the condi-
tions. Since the genes failed the FDR ≤ 0.05 threshold they
were not included in the DiffList and, therefore, were not
included in the pathway enrichment analyses. They are
nevertheless noteworthy because of the specific expres-
sion in one of the two conditions.
Interactions of KEGG biological pathways for genes differen- tially expressed in AAA Figure 3
Interactions of KEGG biological pathways for genes differen-
tially expressed in AAA. The 21 most significant pathways are 
shown (see Table 2 for details). Areas represent pathway 
size (number of genes) and darker shades indicate the pro-
portion of differentially expressed genes of the total number 
of genes in the pathway. See Methods section for details on 
how the interactions were identified.BMC Genomics 2007, 8:237 http://www.biomedcentral.com/1471-2164/8/237
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There is increased expression of genes in the activation sig-
naling that begins with KLRK1  (NKG2D) and HCST
(DAP10). Although this signaling is activating, it does not
utilize an immunoreceptor tyrosine-based activation
motif (ITAM). Interestingly, the activation is specific for
certain downstream intermediates while ITAM signaling is
relatively insensitive to the isoform of the intermediates
[49]. In particular, HCST signals through PLCG2 in prefer-
ence to PLCG1, and through VAV1 in preference to either
of the other two VAV genes [50,51]. This phenomenon fits
well with the observed expression patterns, since PLCG2 is
significantly increased in AAA while PLCG1  is signifi-
cantly decreased, and VAV1 is expressed (unlike VAV2)
and is among the 100 most differential genes (see Figure
1).
Activation of the NK pathway is suggested by the expres-
sion of several of the end-products exclusively in AAA
(PRF1, GZMB), as well as the significant increase of other
end-products from this pathway (CASP3, BID). FAS ligand
(FASLG) expression, another possible end-product of this
pathway, was not detected. Since FASLG is not generally
stored in the immune cells that utilize it [48], lack of
expression indicates that the Fas/FasL system is unlikely to
be involved in the pathology of AAA. Taken together,
these findings fit well with the granule exocytosis pathway
Modified "natural killer cell mediated cytotoxicity" (hsa04650) pathway from KEGG Figure 4
Modified "natural killer cell mediated cytotoxicity" (hsa04650) pathway from KEGG. Protein symbols were replaced by gene 
symbols to reflect gene-centric data. See key for explanation of colors and symbols. Gene symbols were not italicized for bet-
ter legibility [see additional file 4: Table III for expression values of the genes in both conditions as well as the FDR value for 
those that were significantly different].BMC Genomics 2007, 8:237 http://www.biomedcentral.com/1471-2164/8/237
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model of cytotoxicity, and support previous findings in
AAA.
The process of immune cell infiltration represented by the
LTEM pathway [see additional file 3: Figure I] is also bio-
logically relevant to AAA. The presence of immune cells,
as well as the cell types comprising the infiltrate, has pre-
viously been shown in AAA tissue [25,28,46]. We
observed significantly increased expression of several
molecules attributed to leukocytes (ITGB2,  ITGAM,
CXCR4) and in some cases a specificity to AAA (ITGAL,
ITGA4, ITK, TXK; Figure 4). Also, the significant decrease
of ITGB1 was seen previously [7], lending further credence
to the changes demonstrated. These data not only confirm
that different leukocytes are present in AAA tissue, but
may help to identify the specific molecules involved in
their infiltration of the aorta for future studies.
The data presented here confirm many of the findings of
previous gene expression studies on AAA using smaller
sets of genes. One study using spotted membrane mac-
roarrays found that 104 of the 1,185 genes tested were dif-
ferentially expressed in AAA [6]. Our data confirmed 41
(39%) of the 104 genes in that the same genes had signif-
icantly different expression and the expression was
increased or decreased in the same condition, i.e., the dif-
ferential expression was in the same direction [6]. Another
macroarray study used the same array and found differ-
ences in 20 genes, of which our data confirmed 13 (65%)
[7]. There were 13 differentially expressed genes in com-
mon between the two macroarray studies, and 10 of these
(77%) were increased or decreased similarly and had an
FDR ≤ 0.05 in our study. Our microarray study differs
from the prior macroarray studies in array type and ana-
lytical techniques. Nevertheless, the high level of confir-
mation of previous observations provides validation for
the current study.
Previous histological studies of AAA confirm many of the
differences observed in our microarray data. For instance,
the specific expression of perforin in AAA was previously
seen using immunohistochemistry [52]. Also, the differ-
ential expression of IL8, confirmed in prior expression
studies [6,7], was previously validated by immunohisto-
chemistry [45]. IL1B, among the most differentially
expressed genes, was also found to be highly differential
in comparisons of protein levels [47]. The consistency
with protein data is useful since it shows that the expres-
sion differences are likely functional.
The present study has several limitations. One specific
sample-related limitation is that the aneurysm tissue used
came from very late-stage disease, when the aneurysm was
large enough for surgery (≥ 5.5 cm). Since several studies
have shown that the risks of surgical resection are not out-
weighed by the risk of rupture until an aneurysm is quite
large (~5.5 cm), the only tissue available is from late-stage
AAA. A time course of gene expression during aneurysm
development could yield valuable results, but this is not
possible with humans.
Bias may have been introduced in the study since our con-
trol tissue was derived from autopsies. Extensive quality
control analyses revealed no detectable differences
between AAA and control RNA [see additional file 6: Fig-
ure II and file 7: Figure III]. Post mortem changes in RNA
have been studied and shown to have an effect on RNA
integrity, but this is both tissue and time dependent and
can be limited [53]. Despite these limitations, post mor-
tem tissues have been used successfully for expression
studies [53,54].
Another sample-related limitation is that the mRNA was
obtained from the entire control abdominal aorta and
from the resected AAA; therefore, expression at specific
sites or layers in the aorta or aneurysm cannot be identi-
fied. It is, however, impractical to obtain highly compara-
ble, anatomically similar aneurysm and aorta tissue.
The incompleteness of gene annotation is yet another lim-
itation of our study, since only 859 (26%) of the 3,274
differentially expressed genes had KEGG annotations and
2,615 (80%) of these genes had GO annotations. We,
therefore, examined enrichment in both KEGG and GO
annotations to assure consistency. Restricting the analysis
to genes with GO and KEGG annotations limits our anal-
yses, but provides greater functional interpretation. Iso-
forms also complicate the analysis and interpretation of
microarray data. The Illumina Sentrix-6 array contains
probes for various specific isoforms of only 1,935 genes.
The biological information that these annotations can
provide is valuable (such as the example of CD86 iso-
forms in the results), but limited not only by our knowl-
edge (and the testability) of the transcript isoforms, but
also by the biological understanding of what these differ-
ences indicate. Future reanalysis of the data, particularly
of the genes that currently lack annotation and analysis of
any new functional information concerning probed iso-
forms, will be useful.
Conclusion
In summary, the expression profiles presented here extend
the evidence for involvement of immunity in non-inflam-
matory AAA. The substantially increased evidence for the
role of cell-mediated cytotoxicity in AAA and the molecu-
lar signaling behind the infiltration of leukocytes, as well
as the comprehensive annotation of the genes that are
involved in these two pathways, add significantly to the
understanding of AAA. Future work to ascertain the con-
tributions of these expression changes to AAA should beBMC Genomics 2007, 8:237 http://www.biomedcentral.com/1471-2164/8/237
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undertaken. The results provided by this study offer new
insights into AAA pathobiology which will help to direct
future research as well as aid in the development of thera-
peutic options for the treatment of AAA.
Methods
Tissue samples, RNA isolation and microarray analysis
Full thickness aortic wall tissue specimens were collected
in RNAlater (Ambion) from patients undergoing AAA
repair operations at the Harper University Hospital,
Detroit, Michigan. Control aortas were all collected
within 24 h of death and snap-frozen in liquid nitrogen.
Control samples were matched to cases using sex, age, and
ethnicity (Table 1). The study was approved by the Insti-
tutional Review Board of Wayne State University, Detroit,
Michigan, and the research carried out was in compliance
with the Helsinki Declaration.
We isolated total RNA from blood vessels as previously
described [5]. Quality of RNA was checked by Agilent Bio-
analyzer and RNA Integrity Scores are shown in Table
1[55]. Sentrix Human-6 Whole Genome Expression Bead-
Chips (Sentrix Human WG-6; Illumina) were used to
identify genes expressed in AAA tissue (n= 6) and from
individuals without AAA (controls; n= 7). We analyzed
samples both individually as well as in pools. Further QC
procedures included examination of raw and adjusted
intensity histograms [see additional file 6: Figure II] and
principal component analysis [see additional file 7: Figure
III] to detect systematic bias. We used the "Detection
Score" to determine expression using the Illumina plat-
form. It is a statistical measure in the BeadStudio software
(version 1.5.0.34), which is computed based on the Z-
value of a gene relative to the Z-value of the negative con-
trols. The Illumina data were adjusted ("normalized")
using a cubic spline function. We identified genes differ-
entially expressed in AAA [see additional file 1: Table I]
using the Illumina custom error model implemented in
BeadStudio. The expression difference score, DiffScore,
takes into account background noise and sample variabil-
ity [56]. The formula for the calculation of the DiffScore
is:
DiffScore = 10 sgn(µcond - µref)log10 (p)
For the Affymetrix microarray analysis, 10 µg of each RNA
pool was processed and analyzed [57]. For the Affymetrix
arrays, raw data were processed with the statistical lan-
guage R using some of the packages provided by the Bio-
conductor project [58]. We used the GC-RMA algorithm
for the adjustment of the data [59]. GC-RMA takes into
account the GC content of the probe sequences when
comparing the expression intensities of the different
probesets.
To combine the Affymetrix and Illumina data, we identi-
fied a common reference gene set (RefList) of 18,057 dis-
tinct genes represented on both platforms (Affymetrix: n=
19,835 and Illumina: n= 20,054). Heatmaps showing dif-
ferential expression, with green representing lower, and
red higher, were generated using the programs Cluster and
TreeView (version 1.0.12) [60].
The microarray data have been deposited to the Gene
Expression Omnibus (GEO) database (Series# GSE7084)
[61].
Real-time quantitative-reverse-transcription PCR
Microarray-based mRNA expression was validated with
RNA isolated from 10 AAAs and 10 controls (Table 1) by
Q-RT-PCR for RUNX3 and SOST using validated TaqMan®
assays available from Applied Biosystems. The Q-RT-PCR
assays were performed using 50 ng of RNA as previously
described [5].
Functional classification of genes
The differentially expressed gene set [see additional file 1:
Table I] was used to identify enriched GO biological proc-
ess categories using the GoHyperG function (GOStats,
Bioconductor) and enrichment in KEGG biological path-
ways using WebGestalt (Web-based Gene SeT AnaLysis
Toolkit) [36-38,62]. The reference gene set comprised the
18,057 distinct genes represented on both Affymetrix and
Illumina arrays. The hypergeometric test was used for sig-
nificance.
Inclusion in KEGG is limited to the proteins/genes with
defined roles in biological processes. As of December
2006 only 3,768 (21%) of the RefList had KEGG annota-
tions. A total of 13,026 (72%) had GO categories. The
KEGG pathways are not entirely separate from one
another. One example of this is the MAPK signaling path-
way, which is a constituent component in several other
biological pathways, such as the NK pathway. Within the
pathways of the KEGG database there are multiple refer-
ences to other KEGG pathways indicated by a rectangle
with rounded corners inserted into the pathway diagrams
(as can be seen in Figure 4). This interconnectedness
information was manually extracted from the KEGG path-
ways. The nature and complexity of these interactions var-
ied from pathway to pathway, and for simplicity a line
connecting two KEGG pathways was used to represent
these interactions. The interaction map was created using
CytoScape software to generate a framework of the inter-
actions of the enriched KEGG pathways, and the publica-
tion images were produced in Adobe Illustrator (version
12.0.1) [63].BMC Genomics 2007, 8:237 http://www.biomedcentral.com/1471-2164/8/237
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